Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 8 clinical trials
featured
A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected with Chronic HCV who have Advanced Liver Disease or are Post-Liver Transplant

A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected with Chronic HCV who

  • 444 views
  • 08 Nov, 2020
  • 1 location
Re-treatment of HCV Following DAA Failure

HCV infection is treated with oral drugs, termed as 'direct-acting anti-viral agents' (DAAs). In India, four DAAs are available (sofosbuvir [SOF], daclatasvir [DCV], ledipasvir [LDV] and

liver disease
cirrhosis
ledipasvir
hcv genotype
sofosbuvir
  • 19 views
  • 11 Apr, 2021
  • 2 locations
Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy

This is a prospective, controlled, open-label, pharmacokinetic study. This study aims at studying the PK of ledipasvir, sofosbuvir, and GS-331007 metabolite in HCV infected children with

  • 0 views
  • 22 Jan, 2021
  • 1 location
Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir

This study aims to evaluate the efficacy, safety and feasibility of four weeks of sofosbuvir plus glecaprevir-pibrentasvir, followed by immediate retreatment of virological relapse with glecepravir-pibrentasvir for 12 weeks, in treatment-nave participants with chronic HCV infection and early liver disease (F0-F2).

  • 0 views
  • 02 Mar, 2021
  • 3 locations
Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19)

COVID 19 which started from a zoonotic transmission related to crowded markets was confirmed to have a high potential for transmission to close contacts on 20 January 2020 by the National Health Commission of China and it was announced as a pandemic by the WHO on 11 March 2020. There …

  • 0 views
  • 05 Mar, 2021
  • 1 location
Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C

Clinical trials evaluating DAA have shown excellent rates of SVR and good safety profiles in patients with CHC infection. Real world data from TARGET, TRIO, IFI, DHCR, DALTON-C, as well as those cohorts from Japan, Taiwan and Korea further confirmed clinical trial findings of DAA in routine practice where populations …

  • 0 views
  • 19 Jul, 2021
  • 10 locations
Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea

The primary objective of this post-marketing surveillance study is to collect and assess data related to the safety and effectiveness of Harvoni (ledipasvir/sofosbuvir (LDV/SOF)) treatment

ledipasvir/sofosbuvir
treatment regimen
harvoni
chronic hepatitis
ledipasvir
  • 32 views
  • 19 Jul, 2021
  • 94 locations
HCV RAS Testing in Public Health Programs

effect of RASs on sustained virological response (SVR) rates in patients with treatment failure to a regimen containing sofosbuvir and ledipasvir/daclatasvir.

direct acting antivirals
chronic hepatitis
ledipasvir
sofosbuvir
daclatasvir
  • 0 views
  • 23 Jan, 2021
  • 2 locations